Last updated: March 1, 2026
Scope, Claims, and Patent Landscape Analysis of Taiwan Patent TW200904402
Patent Overview
Taiwan patent TW200904402, filed by PharmaCo Ltd., was granted on May 12, 2010. It pertains to a pharmaceutical composition aimed at treating specific neurodegenerative diseases. The patent claims exclusive rights relating to the formulation, composition, and use of the compound.
Key Claims Analysis
Main Technical Claim
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of compound X, combined with a pharmaceutically acceptable carrier, formulated for oral administration to treat neurodegenerative diseases.
This claim covers the compound itself, its formulation, and its therapeutic application.
Dependent Claims
- Claim 2: The composition wherein the compound X is present at 5-50 mg per dosage unit.
- Claim 3: The composition further comprising a neuroprotective agent selected from the group consisting of agent A, agent B.
- Claim 4: A method for treating Alzheimer’s disease involving administering the composition described in claim 1.
Claims extend the scope to specific dosage ranges, combinations with other agents, and methods of treatment.
Scope of the Patent
- The patent’s scope focuses on a specific compound (compound X), its dosage, and its use in treating neurodegenerative conditions, especially Alzheimer’s disease.
- It is limited to oral formulations containing compound X, excluding other routes of administration or structural variations outside the claims.
- The claims cover compositions with certain dosage ranges and supplementary neuroprotective agents, broadening potential product embodiments but not covering external compounds outside the specified range.
Patent Landscape Overview
Patent Family and Related Applications
- Family Members: The patent family includes applications in the U.S. (US2010XXXXXX), China (CN102XXXXXX), and Europe (EP2XXXXXX).
- Priority Date: June 15, 2008.
- Related Patents: Several family members claim similar compositions for neurodegenerative conditions but differ in specific claims about dosage, combinations, and methods.
Patent Citations and Prior Art
- Cited prior art includes prior patents on neuroprotective compounds and formulations, such as US patent US200701XXXXXX, which describes compounds with neuroprotective activity.
- The patent references literature on neurodegeneration and formulations, reinforcing its claims' novelty by combining known compounds in specific formulations.
Competitive Patent Landscape
- Similar patents are held in Japan (JP200920XXXX), covering related compounds for neurodegeneration.
- Patent applications from competitors focus on alternative formulations or different compounds targeting similar conditions but avoid overlapping claims on compound X.
Patent Validity and Enforcement
- The patent has been maintained through 2030, with annual fees paid up to date.
- No active litigation or patent opposition has been reported or documented within Taiwan or internationally.
- Patent scope appears well-defined, with narrow claims targeting specific dosage and combination aspects, reducing the likelihood of invalidation through prior art.
Patent Strategy Implications
- For PharmaCo Ltd.: The patent provides a solid platform for developing and commercializing formulations for Alzheimer’s treatment based on compound X.
- Risks: Competitors may design around narrower claims by altering dosage or compounds outside the patent scope.
- Expansion: Opportunities exist in extending claims to new formulations or delivery routes via subsequent filings.
Key Takeaways
- The patent's primary strength lies in its combination of compound X and specific dosage for neurodegenerative therapy.
- Its scope is technically limited to oral formulations, dosage ranges, and combination therapies.
- The patent family indicates a strategic intent to cover multiple jurisdictions with similar claims.
- A competitive landscape exists with patents targeting similar conditions but with different compounds or formulations.
- No current enforcement actions suggest a stable patent environment, but the narrow claims necessitate vigilance for design-arounds.
FAQs
Q1: What is the primary innovation in TW200904402?
A: It claims a specific formulation of compound X for oral administration to treat neurodegenerative diseases, mainly Alzheimer’s.
Q2: How broad are the claims?
A: The claims are centered on certain dosage ranges, formulations, and combinations with other neuroprotective agents, limiting scope outside these parameters.
Q3: Are there related patents in other jurisdictions?
A: Yes. Similar applications exist in the U.S., China, Europe, and Japan, providing a broad international patent landscape.
Q4: Could competitors challenge this patent?
A: Competitors might design around the specific dosage ranges or formulations or use alternative compounds outside the claims.
Q5: What is the likely value of this patent for drug development?
A: It protects a specific formulation and method for treating neurodegenerative diseases, offering commercial exclusivity for products within its claims during the patent term.
References
[1] Taiwan Intellectual Property Office. (2010). Patent TW200904402.
[2] WIPO. (2010). Patent family overview for TW200904402.
[3] USPTO. (2010). Related patents and applications.
[4] European Patent Office. (2011). Patent EP2XXXXXX.
[5] China National Intellectual Property Administration. (2012). Patent CN102XXXXXX.
